PMH36 ESTIMATED UNITED STATES INCIDENCE AND COST OF EMERGENCY DEPARTMENT STAFF ASSAULTS PERPETRATED BY AGITATED ADULT PATIENTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER  by Hankin, CS et al.
A110 Abstracts
PMH32
IMPACT OF PERSISTENCE WITH BIPOLAR DISORDER TREATMENT 
REGIMES INVOLVING MOOD STABILIZERS,ANTIPSYCHOTICS, 
ANTIDEPRESSANT THERAPY
Bang SI1, Chang JY2, Poon JL1, Suh JK3, McCombs J4
1University of Southern California, Los Angeles, CA, USA, 2University of Southern California, 
Alhambra, CA, USA, 3University of Southern California, LA, CA, USA, 4USC School of 
Pharmacy, Los Angeles, CA, USA
OBJECTIVES: To compare augmentation episodes for patients with bipolar disorder 
to determine the cost implications of both the augmented and augmenting drug thera-
pies and identify other clinical factors that inﬂuence net medical costs. METHODS: 
A retrospective claims analysis was conducted using data from a US commercial insur-
ance company for bipolar disorder patients aged 18 to 65. Episodes of augmentation 
therapy were identiﬁed in which a second psychotropic medication was added to a 
pre-existing drug regimen and the initial drug was continued for more than 60 days. 
Regression analyses were performed comparing patients on mood stabilizers [MS], 
antipsychotics [AP] or antidepressants [AD] as the initial drug to determine which 
augmented therapy was associated with the lowest cost. An analysis of MS, AP or AD 
as the second (augmenting) drug was conducted to determine which augmentation 
therapy led to the lowest cost. In addition, the effect of 25 clinical variables, including 
related co-morbidities of bipolar disorder were also investigated. RESULTS: A total 
of 62,411 episodes of augmentation therapy were identiﬁed. Post-treatment costs for 
the augmentation episode are signiﬁcantly higher if the augmented drug is an AD 
[$653.19, p = 0.05] or an AP [$2,588.86, p < 0.01] compared to episodes with MS 
as the augmented drug. We found no difference in net medical costs across all three 
classes of augmenting drugs. Most baseline clinical variables were statistically signiﬁ-
cant. However, bipolar depression, anxiety and suicide were not found to be signiﬁ-
cant cost factors in all but the subgroup initially on AD. Additionally, patient aged 
over 35 years contributed signiﬁcantly to cost in all three subgroups. CONCLU-
SIONS: Patients who augment a pre-existing MS drug regimen with either AP or AD 
incur the lowest medical costs. This is consistent with bipolar treatment guidelines 
encouraging MS maintenance therapy with AP or AD augmentations.
PMH33
COMPARISON OF COSTS AND HEALTH CARE UTILIZATIONS IN 
PHARMACOTHERAPY, PSYCHOTHERAPY, AND COMBINED THERAPY 
GROUPS FOR TREATMENT OF DEPRESSION
Luthra R, Helm ME, Li C, Said Q
University of Arkansas for Medical Sciences, Little Rock, AR, USA
OBJECTIVES: To compare costs and health care utilizations in pharmacotherapy, 
psychotherapy, and combined therapy groups for treatment of depression. METHODS: 
Depressed individuals 18–65 years were identiﬁed from 1998–2006 Medical Expen-
diture Panel Survey. Individuals with other mental health illnesses were excluded. 
Three mutually exclusive groups were formed: (1) Pharmacotherapy group had at least 
four antidepressant prescriptions yearly and no psychotherapy, (2) Psychotherapy 
group had at least four psychotherapy visits yearly and no antidepressants, (3) Com-
bined therapy group included patients with at least four psychotherapy visits and four 
antidepressants yearly. Yearly mean costs and utilizations were estimated for the three 
groups using generalized linear regression models adjusted for demographics, geo-
graphic diversity, income status, insurance type, perceived mental and physical health 
status, and co-morbidities. RESULTS: Combined therapy group had the highest total 
health care cost ($10610) followed by pharmacotherapy ($7464) and psychotherapy 
groups ($5371), (p-value for differences among the three groups [p] < 0.0001). Mental 
health-related costs for combined therapy, pharmacotherapy and psychotherapy 
groups were $1233, $766 and $516 respectively (p < 0.0001). Ambulatory costs were 
highest for the combined therapy group ($4686) followed by the psychotherapy group 
($3126) and pharmacotherapy group ($2241), (p < 0.0001). Inpatient cost for the 
combined therapy, pharmacotherapy and psychotherapy groups were $2185, $2112, 
and $638, respectively (p = 0.001). Prescription cost was $3451 for combined therapy 
group, $2895 for pharmacotherapy group and $1423 for psychotherapy group (p < 
0.0001). Number of ambulatory visits for combined therapy, pharmacotherapy, and 
psychotherapy groups was 32.24, 11.36, and 22.36, respectively (p < 0.0001). Com-
bined therapy group had the maximum number of prescriptions (42.23), followed 
by the pharmacotherapy group (38.94) and psychotherapy group (17.19), (p < 
0.0001). CONCLUSIONS: Combined therapy group was the highest and psycho-
therapy group was the lowest in terms of costs and utilization for each component 
analyzed. Health decision makers may consider both effectiveness and costs for each 
treatment type.
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DIRECT HEALTH CARE COSTS AMONG PATIENTS WITH BIPOLAR 
DISORDER WHO INITIATED THERAPY WITH ARIPIPRAZOLE OR 
QUETIAPINE XR
Pelletier E1, Smith D1, Hassan M2, Kim J2, Alemayehu B1
1IMS Health Incorporated, Watertown, MA, USA, 2AstraZeneca Pharmaceuticals LP, 
Wilmington, DE, USA
OBJECTIVES: To compare changes in total and mental health-related costs after 
initiation of treatment with aripiprazole (ARP) or extended-release quetiapine (QTP 
XR) among patients with bipolar disorder (BD) in managed care plans. METHODS: 
A retrospective cohort study using US claims data assigned adult patients with BD to 
ARP or QTP XR cohorts based on ﬁrst prescription ﬁlled between June 1, 2007 and 
June 30, 2008. The index date was the date of treatment initiation. Patients were 
continuously insured from 6 months before through 6 months after the index date. 
Per-patient changes in total and mental health-related costs over this period were 
compared using Wilcoxon rank-sum tests. RESULTS: A total of 287 patients with BD 
were initiated on QTP XR and 4554 were initiated on ARP. Reductions in total and 
mental health-related costs were greater among patients initiated on QTP XR than 
patients on ARP. Mean per patient reduction in costs for total health-related services 
was $1368 for QTP XR and $8 for ARP (P = 0.0290). Mean mental health-related 
costs were reduced by $1303 with QTP XR compared with an increase of $302 per 
patient (P < 0.001) with ARP. Average per-patient reduction in all-cause hospitaliza-
tion costs was $2577 for QTP XR and $1394 for ARP (P = 0.0064), and the reduction 
in mental health-related hospitalization costs was $2195 for QTP XR and $1038 for 
ARP (P = 0.0028). The increase in average total pharmacy costs was $1229 for QTP 
XR and $1543 for ARP per patient (P = 0.0219). The increase in average mental 
health-related pharmacy costs was $1163 for QTP XR and $1451 for ARP (P < 0.01). 
There were no differences in mean total and mental health-related outpatient costs 
between treatments.CONCLUSIONS: Patients with BD initiated on QTP XR had 
signiﬁcantly greater reductions in mean total and mental health-related costs compared 
with patients initiated on ARP.
PMH35
COMPARATIVE EFFECTIVENESS OF LONG-ACTING RISPERIDONE:  
A REPORT OF RESOURCE UTILISATION AND COSTS IN A 12 MONTH 
MIRROR-IMAGE ANALYSIS
Carswell C1, Wheeler A2, Vanderpyl J3, Robinson E4
1Adis Journals, Editorial Ofﬁce, Auckland, New Zealand, 2Waitemata DHB/University of 
Auckland, Auckland, New Zealand, 3Te Pou, Auckland, New Zealand, 4University of 
Auckland, Auckland, New Zealand
OBJECTIVES: To explore real-world outcomes and costs of patients treated with 
risperidone long-acting injection (RLAI) in New Zealand. METHODS: A mirror-
image retrospective study was conducted comparing outcomes and costs 12 months 
post- versus 12 months pre-initiation of RLAI in adults approved for treatment 
between October 2005-October 2006 in 5 health services. Continuation rates, com-
pulsory treatment status, psychiatric hospitalisation (admission number, bed-stay and 
cost), and treatment data were collected for twelve months on either side of ﬁrst RLAI 
prescription. Hospitalisation costs were valued using estimates for cost/admission and 
cost/bed-day ($NZ, 2009 values). RESULTS: 58.3% of patients remained on RLAI 
12 months after initiation. The average number of admissions for the total study 
population was signiﬁcantly less in the post-RLAI period (1.38 vs 0.61, p < 0.001) 
but average length of bed-stay increased (37.2 vs 53.3 days, p < 0.001) as did com-
pulsory treatment use. Overall bed-nights increased by 6877 in the post-RLAI period 
driven mostly by those who discontinued treatment. Patients who continued RLAI 
had fewer admissions and days in hospital post-RLAI compared to patients who 
discontinued RLAI in the ﬁrst year. The reduction in total hospital admission rates 
between the two treatment periods was signiﬁcantly greater in continuation group and 
mean difference in bed-days between the two treatment periods was signiﬁcantly less 
for continuers (5.4 vs. 31.1 days, p < 0.001). Applying a cost/admission, hospitalisa-
tion costs reduced by approximately $NZ1 million in the post RLAI-period. Applying 
a daily hospitalisation cost resulted in an increase of approximately $NZ3.5 million 
in the post-RLAI period. CONCLUSIONS: study suggests that patients have reduced 
hospital admissions but longer bed-stay after starting RLAI. Longer admissions were 
driven by those that discontinued treatment and continuation was associated with 
improved resource and cost outcomes compared to those who discontinued. These 
ﬁndings have potential implications for payers, providers and patients, requiring 
further investigation over a longer timeframe.
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ESTIMATED UNITED STATES INCIDENCE AND COST OF EMERGENCY 
DEPARTMENT STAFF ASSAULTS PERPETRATED BY AGITATED ADULT 
PATIENTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER
Hankin CS1, Norris MM2, Bronstone A1
1BioMedEcon, LLC, Moss Beach, CA, USA, 2Mount Sinai School of Medicine, New York, 
NY, USA
OBJECTIVES: The annual United States (U.S.) incidence of emergency department 
(ED) staff assaults perpetrated by agitated adult patients with schizophrenia or bipolar 
disorder is difﬁcult to quantify, given staff tendencies toward under-reporting, differ-
ing deﬁnitions of assaultive behaviors, and the broad array of data collection methods 
used. Based on a review of the published literature, we sought to estimate the 1-year 
U.S. incidence and associated costs of patient assaults on ED staff. METHODS: 
Systematic literature review and meta-analysis of published literature from January 1, 
1966-December 31, 2009 using MEDLINE terms: ((“Psychomotor Agitation” OR 
“Aggression”) OR “Violence”) AND “Emergency Service, Hospital” AND 
(English[lang] AND “adult”). “True” annual incidence was calculated as the average 
annualized number of reported assault cases divided by the percent of actual incidence 
represented by these cases. Costs, assessed from the hospital perspective, were calcu-
lated for work days lost by victimized staff. RESULTS: There were 512 publications 
identiﬁed, of which 23 were included. Among an estimated 119 million annual U.S. 
ED visits, patients with schizophrenia or bipolar disorder accounted for 0.8% 
(952,000) and 4–9% (4.8–10.7 million) of visits, respectively. On average, ED nurses 
(N = 31,905) and physicians (N = 17,000) each reported 2.75 and 3.4 annual physical 
assaults (total 145,539) perpetrated by patients. According to staff surveys, approxi-
mately 65% of actual assaults upon staff were unreported. The “true” annual inci-
dence of assaults on ED staff perpetrated by patients with schizophrenia or bipolar 
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disorder appears to exceed 415,000 [31,905 x (2.75/35%)] + [17,000 x (3.4/35%)]. 
On average, 1.5 work days are lost by staff following patient assault at an annual cost 
of $444.4 million (based on hourly pay rates for nurses and doctors of $41 and $162, 
respectively). CONCLUSIONS: Rapid and effective de-escalation of agitation among 
patients with schizophrenia or bipolar disorder seeking care in the ED may reduce the 
incidence and associated costs of staff assaults.
PMH37
CHARACTERISTICS OF HOSPITALIZATIONS FOR ATTENTION-DEFICIT/
HYPERACTIVITY DISORDER (ADHD) AMONG CHILDREN AND 
ADOLESCENTS IN THE UNITED STATES FROM 2000–2006
Classi P1, Meyers J2, Wietecha L1, Candrilli S2
1Eli Lilly and Company, Indianapolis, IN, USA, 2RTI Health Solutions, Research Triangle Park, 
NC, USA
OBJECTIVES: The aim of this research was to evaluate patient characteristics, length 
of stay (LOS), and costs among children and adolescents hospitalized in the United 
States (US) for ADHD. METHODS: The study used data from 2000–2006 in the 
Healthcare Cost and Utilization Project Nationwide Inpatient Sample (HCUP-NIS). 
Patients included were children (6–11 years old) and adolescents (12–17 years old) 
that were hospitalized with a primary diagnosis of ADHD (ICD-9-CM 314.00 or 
314.01). Data collected includes age, gender, race, payer type, admission source, 
admission type, geographic region, hospital status, year admitted, mean LOS and 
mean costs. RESULTS: Among children, 28,247 patients met inclusion criteria and 
83.74% were male. Medicaid was the most common form of health insurance 
(68.97%) followed by private insurance (26.67%). The majority of patients were 
hospitalized in urban locations (96.69%) and were admitted from the emergency room 
(33.75%). Mean (SE) LOS was 10.76 days (0.85) and mean (SE) costs were $10,106 
($1,358). Among adolescents, 21,612 patients met inclusion criteria and 75.70% were 
male. Medicaid was the most common form of health insurance (57.38%) followed 
by private insurance (36.99%). The majority of patients were hospitalized in urban 
locations (93.83%) and admitted from the emergency room (38.77%). Mean (SE) 
LOS was 8.66 days (0.66) and mean (SE) costs were $7886 ($1387). The number of 
hospitalizations for ADHD in each individual year from 2000–2006 was fairly con-
stant for both children and adolescents. CONCLUSIONS: Children and adolescents 
hospitalized for ADHD carry a substantial economic burden to the US health care 
system. The majority of these patients are male, come from urban locations and have 
Medicaid as their primary form of health insurance. Health care decision makers 
should be aware of the burden of ADHD in these populations. Research evaluating 
the impact of behavioural and/or pharmalogical ADHD treatment on hospitalizations 
should be explored.
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SOCIETAL COSTS OF OPIOID ABUSE, DEPENDENCE, AND MISUSE IN 
THE UNITED STATES
Birnbaum H1, White A1, Schiller M1, Waldman T1, Cleveland JM2, Setnik BS2, Pixton GC2, 
Roland CL2
1Analysis Group, Inc., Boston, MA, USA, 2King Pharmaceuticals, Inc., Cary, NC, USA
OBJECTIVES: Estimate the current societal costs of opioid abuse, dependence, and 
misuse. METHODS: Costs associated with opioid abuse were grouped into three 
major categories: health care, workplace, and criminal justice. Two general principles 
were adopted to estimate costs: 1) a quantity method, which multiplies the number 
of opioid abuse patients by the estimated cost per opioid abuse patient, and, 2) an 
apportionment method, which begins with the overall costs of drug abuse for a cost 
component and apportions the share associated with opioid abuse based on the rela-
tive prevalence of opioid abuse to overall drug abuse. Excess health care costs per 
patient were based on analysis of two claims datasets: a privately-insured population 
and Florida Medicaid. Other data/information was derived from publicly-available 
secondary resources (e.g., academic research, government reports and surveys). 
RESULTS: Total societal costs of opioid abuse in the U.S. were estimated at $54.5 
billion annually (2008 dollars). Disaggregated by major category, workplace costs 
accounted for $25.1 billion (46%), health care costs accounted for $24.2 billion 
(44%), and criminal justice costs accounted for $5.2 billion (10%). Workplace costs 
were driven by lost earnings due to premature death ($11.1 billion) and reduced 
compensation/lost employment associated with opioid abuse ($7.8 billion). Health 
care costs consisted primarily of excess medical and prescription drug costs for opioid 
abuse patients ($23.0 billion). Criminal justice costs were largely made up of cor-
rectional facility costs attributable to opioid abuse ($2.3 billion) and police protection 
costs attributable to opioid abuse ($1.5 billion). CONCLUSIONS: The costs of opioid 
abuse represent a substantial and growing economic burden for society in the U.S. 
The increasing prevalence of abuse and related spending suggest an even greater 
societal burden in the future. Recent initiatives developed by the government, clini-
cians, and the health care industry may help reduce the burden of opioid abuse.
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COST OF ILLNESS OF POST-TRAUMATIC STRESS DISORDER 
COMPARED WITH MAJOR DEPRESSIVE DISORDER
Ivanova J1, Birnbaum H2, Chen L3, Dayoub E2, Kantor E2, Phillips G3
1Analysis Group, Inc., New York, NY, USA, 2Analysis Group, Inc., Boston, MA, USA, 3Eli Lilly 
and Company, Indianapolis, IN, USA
OBJECTIVES: Compare health care costs of patients with post-traumatic stress dis-
order (PTSD) to those of patients with major depressive disorder (MDD) in U.S. 
Medicaid and privately-insured populations. METHODS: Patients with ≥2 PTSD 
diagnoses (ICD-9-CM: 309.81) on/after January 1, 1999 and ≥1 PTSD diagnosis on/
after January 1, 2003 were identiﬁed from Medicaid claims data from Florida, 
Missouri, and New Jersey (1999–2007) and from a privately-insured claims database 
(1999–2008). The index date was deﬁned as the ﬁrst PTSD diagnosis on/after 1/1/2003 
that was not the ﬁrst overall PTSD diagnosis. PTSD patients had continuous eligibility 
for the 6-month baseline period before and 12-month study period following their 
index date and were ages 18–64 during the study period. Potential MDD controls 
(ICD-9-CM: 296.2, 296.3) without PTSD diagnosis were identiﬁed using similar 
selection criteria. MDD controls were matched to PTSD patients on age, gender, 
state/region, employment status, index year, and race (for Medicaid patients). 
Study period direct costs, calculated as reimbursements in 2008 dollars to third-party 
payers for medical services and prescription drugs, were compared between PTSD 
patients and matched MDD controls using nonparametric bootstrapping. RESULTS: 
In the baseline period, PTSD patients had higher rates of other mental disorders 
(e.g. anxiety, bipolar disorder), and higher average direct costs than MDD controls 
both in the Medicaid and privately-insured populations. Among Medicaid patients, 
PTSD patients also had lower average Charlson Comorbidity Index compared 
with MDD controls. Average study period direct costs were higher for PTSD patients 
than MDD controls ($18,753 vs. $17,990 for Medicaid and $10,960 vs. $10,024 for 
privately-insured, both p < 0.05). The difference in direct costs was driven by higher 
mental health-related costs for PTSD patients than for MDD controls. CONCLU-
SIONS: PTSD patients had approximately 4–10% higher direct costs in the 12-month 
study period compared to MDD controls driven by higher mental-health related direct 
costs.
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PATTERNS OF HEALTH CARE UTILIZATION AND COSTS IN PATIENTS 
WITH GENERALIZED ANXIETY DISORDER INITIATING ADD-ON 
THERAPY WITH BENZODIAZEPINES
Berger A1, Edelsberg J2, Bollu V3, Alvir J4, Dugar A5, Joshi AV6, Oster G1
1Policy Analysis Inc., Brookline, MA, USA, 2PAI, Brookline, MA, USA, 3Novartis 
Pharmaceuticals Corp, East Hanover, NJ, USA, 4Pﬁzer, Inc., New York, NY, USA, 5Pﬁzer, 
New York, NY, USA, 6Pﬁzer Inc., New York, NY, USA
OBJECTIVES: To examine patterns of health care utilization and costs in patients 
with generalized anxiety disorder (GAD) beginning treatment with benzodiazepine 
anxiolytics as add-on therapy to selective serotonin reuptake inhibitors (SSRI) or 
venlafaxine. METHODS: Using a large US health insurance claims database, we 
identiﬁed all persons with evidence of GAD (ICD-9-CM diagnosis code 300.02) who 
were receiving treatment (≥90 days) with SSRIs or venlafaxine between January 1, 
2003 and December 31, 2007. Among these patients, we then selected those who 
began add-on therapy with a benzodiazepine anxiolytic. Designating the date of initial 
receipt of a benzodiazepine the “index date”, we compiled all health care claims over 
the 6-month period preceding this date (“pre-index”) and the 12-month period fol-
lowing it (“follow-up”). Patients with incomplete data were excluded. Health care 
utilization and costs were then examined during these periods. RESULTS: A total of 
2131 patients met all study inclusion criteria. Mean age was 43 years; 73% were 
women. Patients averaged 32 days of therapy with benzodiazepines, however, dura-
tion of therapy was >90 days, for 14% of patients. In general, levels of health care 
utilization during the ﬁrst 6 months of follow-up were higher than during pre-index; 
during the second 6 months of follow-up, however, they were somewhat lower than 
pre-index. Median (IQR) total health care costs were $2672 ($1465-$4960) during 
pre-index, $2897 ($1525–5663) during the ﬁrst 6 months of follow-up, and $2581 
($1270-$5107) during the second 6 months of follow-up. CONCLUSIONS: Overall 
health care utilization and associated costs increased following initial GAD diagnosis. 
Although the duration of treatment is typically brief, some patients receive benzodi-
azepine anxiolytics as add-on therapy to SSRIs or venlafaxine for periods longer than 
90 days, which is not recommended due to risks of dependency and sedation.
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THE SOCIETAL COST OF SCHIZOPHRENIA IN SWEDEN
Ekman M1, Granström O2, Omerov S3, Jacob J2, Landén M4
1i3 Innovus, Stockholm, Sweden, 2AstraZeneca Nordic MC, Södertälje, Sweden, 3Northern 
Stockholm Psychiatry, Stockholm, Sweden, 4Gothenburg University, Göteborg, Sweden
OBJECTIVES: To investigate the health care resource utilization and cost-of-illness 
in patients with schizophrenia in Sweden. METHODS: Data on socio-demographics 
and disease-related health care resource use for 2412 patients were collected using 
registry data for the period 2006–2008. Data on health care visits and inpatient days 
were obtained from the Northern Stockholm psychiatric clinic, while data on phar-
maceuticals, sick leave and early retirement were obtained from the national pharma-
ceutical registry and the Swedish social insurance agency, respectively. Costs for 
community care were not available on individual level in the databases, and were 
therefore obtained from previous studies. The study was conducted from a societal 
perspective, with indirect costs valued according to the human capital method. 
RESULTS: The average annual cost per patient with schizophrenia in the period 
2006–2008 was estimated at 348,300o (US$68,800) in 2009 prices. Total costs 
increased by 8% from 2006 to 2008, mainly because of increased indirect costs. 
Outpatient care represented 5%, inpatient care 9%, pharmaceuticals 3%, community 
care 24% and productivity losses 59% of total costs. Costs (excluding community 
care cost, which was not available on the individual level) were signiﬁcantly and posi-
tively correlated with lower functioning as assessed with GAF (General Assessment of 
Functioning). Costs in the lowest GAF class (GAF < 50) were almost three times as 
large as in the highest GAF class (GAF > = 70). Men had signiﬁcantly higher indirect 
